Targeting the acute myeloid leukemic stem cell compartment by enhancing tumor cell-based vaccines

Jurjen M Ruben, Lindy L Visser, Hetty J Bontkes, Theresia M Westers, Gert J Ossenkoppele, Tanja D de Gruijl, Arjan A van de Loosdrecht

Onderzoeksoutput: Bijdrage aan tijdschriftArtikel recenserenpeer review

Samenvatting

Harvesting the potential of the immune system in order to eradicate (residual) acute myeloid leukemia (AML) cells is the long pursued goal of immunotherapy in AML. Strategies using apoptotic tumor cell vaccines have been explored for many years, without significant clinical improvements. In recent years insight has been gained into the mechanisms activating and interfering with tumor-directed immunity. With the arrival of novel immune-modulating agents allowing for the interference with regulatory molecules and interaction with immune-propelling mechanisms, new doors are opening for increasing vaccination efficacy. Combined with advances in the design of apoptotic tumor-based vaccines, we are on the verge of creating an effective AML vaccine strategy, offering a much needed novel therapeutic option for this devastating disease.

Originele taal-2Engels
Pagina's (van-tot)859-68
Aantal pagina's10
TijdschriftImmunotherapy
Volume5
Nummer van het tijdschrift8
DOI's
StatusGepubliceerd - aug. 2013
Extern gepubliceerdJa

Vingerafdruk

Duik in de onderzoeksthema's van 'Targeting the acute myeloid leukemic stem cell compartment by enhancing tumor cell-based vaccines'. Samen vormen ze een unieke vingerafdruk.

Citeer dit